{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T07:45:34Z","timestamp":1791963934039,"version":"4.3.4"},"reference-count":77,"publisher":"American Association for Cancer Research (AACR)","issue":"1","funder":[{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["6675-24"],"award-info":[{"award-number":["6675-24"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA177292"],"award-info":[{"award-number":["R01 CA177292"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA016058"],"award-info":[{"award-number":["P30 CA016058"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015979","name":"Pelotonia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015979","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100025821","name":"American Legion Auxiliary","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100025821","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012684","name":"Center for Clinical and Translational Sciences, University of Texas Health Science Center at Houston","doi-asserted-by":"publisher","award":["TL1TR003169"],"award-info":[{"award-number":["TL1TR003169"]}],"id":[{"id":"10.13039\/100012684","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Inhibition of the tyrosine kinase BTK is a major therapeutic strategy for treating B-cell malignancies, including chronic lymphocytic leukemia (CLL). However, resistance can emerge when tumor cells acquire mutations that abrogate drug binding or when BTK activates B-cell receptor (BCR) signaling by mechanisms independent of its kinase activity. In this study, we identified upregulation of PKC\u03b2 in samples from patients with CLL resistant to BTK inhibitors (BTKi) and characterized the PKC\u03b2 inhibitor MS-553. MS-553 reduced BCR and Wnt\/\u03b2-catenin signaling, overcame stromal cell mediated protection, and synergized with venetoclax in CLL samples. MS-553 also retained the cytotoxicity and inhibition of both BCR and Wnt\/\u03b2-catenin signaling in models (cell lines and primary samples) of covalent BTKi-resistant (C481S BTK) and noncovalent BTKi-resistant (T474I or L528W BTK) CLL. Furthermore, MS-553 delayed disease progression and prolonged survival in the E\u03bc-MTCP1 murine model of CLL. Collectively our results demonstrate that selective inhibition of PKC\u03b2 has the potential to overcome BTKi-resistant CLL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>This study identified and characterized PKC\u03b2 as a therapeutic target in CLL, including CLL resistant to BTKis. Inhibition of PKC\u03b2 suppressed both BCR and Wnt\/\u03b2-catenin signaling, delayed disease progression in vivo, overcame BTKi resistance mechanisms, and enhanced response to BCL-2 inhibition.<\/jats:p>\n                    <jats:p>See related commentary by Jebaraj and Stilgenbauer, p. 21<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-25-0114","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T15:01:57Z","timestamp":1762354917000},"page":"85-103","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["PKC\u03b2 Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Na\u00efve and BTK Inhibitor\u2013Resistant Chronic Lymphocytic Leukemia"],"prefix":"10.1158","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-8751-4435","authenticated-orcid":false,"given":"Britten K.","family":"Gordon","sequence":"first","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6903-0668","authenticated-orcid":false,"given":"Elizabeth M.","family":"Muhowski","sequence":"additional","affiliation":[{"name":"2Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1185-9588","authenticated-orcid":false,"given":"Jyotsana","family":"Singh","sequence":"additional","affiliation":[{"name":"3Division of Hematopoietic Biology and Malignancy, MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0933-3883","authenticated-orcid":false,"given":"Janani","family":"Ravikrishnan","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9091-5679","authenticated-orcid":false,"given":"Arnau","family":"Peris-Cuesta","sequence":"additional","affiliation":[{"name":"3Division of Hematopoietic Biology and Malignancy, MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6286-4910","authenticated-orcid":false,"given":"Daisy","family":"Diaz Rohena","sequence":"additional","affiliation":[{"name":"3Division of Hematopoietic Biology and Malignancy, MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5362-1025","authenticated-orcid":false,"given":"John R.","family":"Sanchez","sequence":"additional","affiliation":[{"name":"3Division of Hematopoietic Biology and Malignancy, MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9542-9050","authenticated-orcid":false,"given":"Shanmugapriya","family":"Thangavadivel","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0465-0231","authenticated-orcid":false,"given":"Samon","family":"Benrashid","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0274-7546","authenticated-orcid":false,"given":"Alexander","family":"He","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1448-7353","authenticated-orcid":false,"given":"Alexander R.","family":"Marr","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2018-4359","authenticated-orcid":false,"given":"Andrew D.","family":"Mitchell","sequence":"additional","affiliation":[{"name":"2Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0434-4308","authenticated-orcid":false,"given":"Jazmin M.","family":"Urrutia","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9656-932X","authenticated-orcid":false,"given":"Shrilekha","family":"Misra","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4318-8042","authenticated-orcid":false,"given":"Tzung-Huei","family":"Lai","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2025-2585","authenticated-orcid":false,"given":"Lianbo","family":"Yu","sequence":"additional","affiliation":[{"name":"4Center for Biostatistics, Department of Biomedical Informatics, The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7068-8894","authenticated-orcid":false,"given":"Brandi R.","family":"Walker","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8325-4287","authenticated-orcid":false,"given":"Elizabeth","family":"Perry","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2445-3584","authenticated-orcid":false,"given":"Sachet A.","family":"Shukla","sequence":"additional","affiliation":[{"name":"3Division of Hematopoietic Biology and Malignancy, MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3495-5932","authenticated-orcid":false,"given":"Nicole R.","family":"Grieselhuber","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5748-7874","authenticated-orcid":false,"given":"Kerry A.","family":"Rogers","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6916-9400","authenticated-orcid":false,"given":"Rosa","family":"Lapalombella","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4275-5562","authenticated-orcid":false,"given":"James S.","family":"Blachly","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4891-6144","authenticated-orcid":false,"given":"Adam S.","family":"Kittai","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7844-0856","authenticated-orcid":false,"given":"Seema A.","family":"Bhat","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0114-8384","authenticated-orcid":false,"given":"Nitin","family":"Jain","sequence":"additional","affiliation":[{"name":"3Division of Hematopoietic Biology and Malignancy, MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7357-270X","authenticated-orcid":false,"given":"William G.","family":"Wierda","sequence":"additional","affiliation":[{"name":"3Division of Hematopoietic Biology and Malignancy, MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8778-1000","authenticated-orcid":false,"given":"John C.","family":"Byrd","sequence":"additional","affiliation":[{"name":"5Department of Internal Medicine, University of Cincinnati, Cincinnati, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6700-8985","authenticated-orcid":false,"given":"Michael","family":"Niesman","sequence":"additional","affiliation":[{"name":"6MingSight Pharmaceuticals Inc., San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4212-282X","authenticated-orcid":false,"given":"Kai","family":"Zhang","sequence":"additional","affiliation":[{"name":"6MingSight Pharmaceuticals Inc., San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4366-8436","authenticated-orcid":false,"given":"Deepa","family":"Sampath","sequence":"additional","affiliation":[{"name":"3Division of Hematopoietic Biology and Malignancy, MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3403-9144","authenticated-orcid":false,"given":"Jennifer A.","family":"Woyach","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"2026011203074142600_bib1","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/ajh.27546","article-title":"Chronic lymphocytic leukemia: 2025 update on the epidemiology, pathogenesis, diagnosis, and therapy","volume":"100","author":"Hallek","year":"2025","journal-title":"Am J Hematol"},{"key":"2026011203074142600_bib2","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"key":"2026011203074142600_bib3","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrc3702","article-title":"Targeting Bruton\u2019s tyrosine kinase in B cell malignancies","volume":"14","author":"Hendriks","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"2026011203074142600_bib4","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"key":"2026011203074142600_bib5","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N Engl J Med"},{"key":"2026011203074142600_bib6","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N Engl J Med"},{"key":"2026011203074142600_bib7","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"key":"2026011203074142600_bib8","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"2026011203074142600_bib9","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/blood-2019-127674","article-title":"Resistance to acalabrutinib in CLL is mediated primarily by BTK mutations","volume":"134","author":"Woyach","year":"2019","journal-title":"Blood"},{"key":"2026011203074142600_bib10","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2300696","article-title":"Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia","volume":"389","author":"Mato","year":"2023","journal-title":"N Engl J Med"},{"key":"2026011203074142600_bib11","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa2114110","article-title":"Mechanisms of resistance to noncovalent Bruton\u2019s tyrosine kinase inhibitors","volume":"386","author":"Wang","year":"2022","journal-title":"N Engl J Med"},{"key":"2026011203074142600_bib12","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/leu.2014.263","article-title":"Functional characterization of BTK C481S mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors","volume":"29","author":"Cheng","year":"2015","journal-title":"Leukemia"},{"key":"2026011203074142600_bib13","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1182\/blood-2024-194748","article-title":"Outcomes of therapies following discontinuation of non-covalent Bruton\u2019s tyrosine kinase inhibitors for patients with chronic lymphocytic leukemia and richter transformation: results from an international, multicenter study","volume":"144","author":"Thompson","year":"2024","journal-title":"Blood"},{"key":"2026011203074142600_bib14","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2008-06-160713","article-title":"PKC\u03b2 is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKC\u03b2 as a therapeutic target in chronic lymphocytic leukemia","volume":"113","author":"Holler","year":"2009","journal-title":"Blood"},{"key":"2026011203074142600_bib15","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1182\/blood-2006-03-012021","article-title":"B-cell receptor signaling in chronic lymphocytic leukemia cells is regulated by overexpressed active protein kinase CbetaII","volume":"109","author":"Abrams","year":"2007","journal-title":"Blood"},{"key":"2026011203074142600_bib16","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.coi.2004.03.012","article-title":"Protein kinase C family functions in B-cell activation","volume":"16","author":"Guo","year":"2004","journal-title":"Curr Opin Immunol"},{"key":"2026011203074142600_bib17","doi-asserted-by":"crossref","first-page":"16878","DOI":"10.1016\/S0021-9258(18)41866-2","article-title":"Differential regulation of glycogen synthase kinase-3\u03b2 by protein kinase C isotypes","volume":"267","author":"Goode","year":"1992","journal-title":"J Biol Chem"},{"key":"2026011203074142600_bib18","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"key":"2026011203074142600_bib19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccr.2012.12.003","article-title":"Protein kinase C-\u03b2-dependent activation of NF-\u03baB in stromal cells is indispensable for the survival of chronic lymphocytic leukemia B cells in vivo","volume":"23","author":"Lutzny","year":"2013","journal-title":"Cancer Cell"},{"key":"2026011203074142600_bib20","doi-asserted-by":"crossref","first-page":"9340","DOI":"10.1126\/scitranslmed.aax9340","article-title":"Stromal cell protein kinase C-\u03b2 inhibition enhances chemosensitivity in B cell malignancies and overcomes drug resistance","volume":"12","author":"Park","year":"2020","journal-title":"Sci Transl Med"},{"key":"2026011203074142600_bib21","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1182\/blood-2014-05-574830","article-title":"PKC-\u03b2 as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL","volume":"124","author":"El-Gamal","year":"2014","journal-title":"Blood"},{"key":"2026011203074142600_bib22","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1200\/JCO.2006.09.3146","article-title":"Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"25","author":"Robertson","year":"2007","journal-title":"J Clin Oncol"},{"key":"2026011203074142600_bib23","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s00280-010-1410-1","article-title":"A phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies","volume":"67","author":"Fracasso","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026011203074142600_bib24","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s10637-009-9220-1","article-title":"A phase II study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and a taxane containing regimen","volume":"27","author":"Mina","year":"2009","journal-title":"Invest New Drugs"},{"key":"2026011203074142600_bib25","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1038\/s41416-022-02133-6","article-title":"A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma","volume":"128","author":"Piperno-Neumann","year":"2023","journal-title":"Br J Cancer"},{"key":"2026011203074142600_bib26","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ygyno.2007.02.018","article-title":"UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: a study of the Princess Margaret Hospital Phase II consortium","volume":"106","author":"Welch","year":"2007","journal-title":"Gynecol Oncol"},{"key":"2026011203074142600_bib27","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1111\/ajt.13175","article-title":"Protein kinase C inhibitor sotrastaurin in de novo liver transplant recipients: a randomized phase ii trial","volume":"15","author":"Pascher","year":"2015","journal-title":"Am J Transplant"},{"key":"2026011203074142600_bib28","doi-asserted-by":"crossref","first-page":"6193","DOI":"10.1021\/jm901108b","article-title":"Discovery of 3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4- yl]-pyrrole-2,5-dione (AEB071), a potent and selective inhibitor of protein kinase C isotypes","volume":"52","author":"Wagner","year":"2009","journal-title":"J Med Chem"},{"key":"2026011203074142600_bib29","doi-asserted-by":"crossref","first-page":"7462","DOI":"10.1158\/0008-5472.CAN-05-0071","article-title":"The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts","volume":"65","author":"Graff","year":"2005","journal-title":"Cancer Res"},{"key":"2026011203074142600_bib30","doi-asserted-by":"crossref","first-page":"681","DOI":"10.21037\/atm.2019.11.105","article-title":"CDK14 involvement in proliferation migration and invasion of esophageal cancer","volume":"7","author":"Chen","year":"2019","journal-title":"Ann Transl Med"},{"key":"2026011203074142600_bib31","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1073\/pnas.1102300108","article-title":"T-cell factor 4 functions as a tumor suppressor whose disruption modulates colon cell proliferation and tumorigenesis","volume":"108","author":"Angus-Hill","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026011203074142600_bib32","doi-asserted-by":"crossref","first-page":"eadi5798","DOI":"10.1126\/science.adi5798","article-title":"Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1\/3 degrader NX-2127","volume":"383","author":"Montoya","year":"2024","journal-title":"Science"},{"key":"2026011203074142600_bib33","article-title":"Novel 3-amino-pyrrolo[3,4-c]pyrazole-5(1h, 4h, 6h) carbaldehyde derivates","author":"Li","year":"2010"},{"key":"2026011203074142600_bib34","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/416860a","article-title":"Protein kinase C\u03b4 controls self-antigen-induced B-cell tolerance","volume":"416","author":"Mecklenbr\u00e4uker","year":"2002","journal-title":"Nature"},{"issue":"Suppl 1","key":"2026011203074142600_bib35","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1182\/blood-2022-171203","article-title":"Initial results from a phase 1\/2 dose escalation and expansion study evaluating MS-553, a novel and selective PKC\u03b2 inhibitor, in patients with CLL\/SLL","volume":"140","author":"Blachly","year":"2022","journal-title":"Blood"},{"key":"2026011203074142600_bib36","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1002\/j.1460-2075.1995.tb07287.x","article-title":"Phosphorylation of human I\u03baB-\u03b1 on serines 32 and 36 controls I\u03baB-\u03b1 proteolysis and NF-\u03baB activation in response to diverse stimuli","volume":"14","author":"Traenckner","year":"1995","journal-title":"EMBO J"},{"key":"2026011203074142600_bib37","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1091\/mbc.e15-09-0624","article-title":"Sequential posttranslational modifications regulate PKC degradation","volume":"27","author":"Wang","year":"2016","journal-title":"Mol Biol Cell"},{"key":"2026011203074142600_bib38","doi-asserted-by":"crossref","first-page":"818688","DOI":"10.3389\/fphys.2022.818688","article-title":"Protein kinase C Life cycle: explained through systems biology approach","volume":"13","author":"Aslam","year":"2022","journal-title":"Front Physiol"},{"key":"2026011203074142600_bib39","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1128\/MCB.25.11.4426-4441.2005","article-title":"A diacylglycerol-protein kinase C-RasGRP1 pathway directs Ras activation upon antigen receptor stimulation of T cells","volume":"25","author":"Roose","year":"2005","journal-title":"Mol Cell Biol"},{"key":"2026011203074142600_bib40","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.it.2013.07.002","article-title":"B cell receptor signaling in chronic lymphocytic leukemia","volume":"34","author":"Burger","year":"2013","journal-title":"Trends Immunol"},{"key":"2026011203074142600_bib41","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/bjh.13659","article-title":"CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma","volume":"171","author":"Takahashi","year":"2015","journal-title":"Br J Haematol"},{"key":"2026011203074142600_bib42","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1182\/blood-2008-07-170415","article-title":"High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation","volume":"113","author":"Burger","year":"2009","journal-title":"Blood"},{"key":"2026011203074142600_bib43","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/S0301-472X(01)00612-9","article-title":"Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5)","volume":"29","author":"Garrido","year":"2001","journal-title":"Exp Hematol"},{"key":"2026011203074142600_bib44","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.4049\/jimmunol.164.4.2200","article-title":"Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells","volume":"164","author":"Furman","year":"2000","journal-title":"J Immunol"},{"key":"2026011203074142600_bib45","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1182\/blood.V97.9.2777","article-title":"Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia","volume":"97","author":"Granziero","year":"2001","journal-title":"Blood"},{"key":"2026011203074142600_bib46","first-page":"e302","article-title":"Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors","volume":"100","author":"Thijssen","year":"2015","journal-title":"Haematologica"},{"key":"2026011203074142600_bib47","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1182\/blood.2019004326","article-title":"Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL","volume":"136","author":"Haselager","year":"2020","journal-title":"Blood"},{"key":"2026011203074142600_bib48","first-page":"6338","article-title":"Rare t(X;14)(q28;q32) translocation reveals link between MTCP1 and chronic lymphocytic leukemia","volume":"12","author":"Walker","year":"2021","journal-title":"Nat Res"},{"key":"2026011203074142600_bib49","first-page":"EP702","article-title":"Initial results of a phase 1 dose escalation study evaluation of MS-553, a novel, selective inhibitor of PKC-beta, in patients with relapsed or refractory CLL\/SLL","volume":"294620","author":"Blachly","year":"2020","journal-title":"Eur Hematol Assoc"},{"key":"2026011203074142600_bib50","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3390\/cancers10040127","article-title":"Responses to the selective Bruton\u2019s tyrosine kinase (BTK) inhibitor tirabrutinib (ONO\/GS-4059) in diffuse large B-cell lymphoma cell lines","volume":"10","author":"Kozaki","year":"2018","journal-title":"Cancers (Basel)"},{"key":"2026011203074142600_bib51","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S1470-2045(23)00452-7","article-title":"Fixed-duration ibrutinib\u2013venetoclax versus chlorambucil\u2013obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Niemann","year":"2023","journal-title":"Lancet Oncol"},{"key":"2026011203074142600_bib52","doi-asserted-by":"crossref","first-page":"EVIDoa2200006","DOI":"10.1056\/EVIDoa2200006","article-title":"Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities","volume":"1","author":"Kater","year":"2022","journal-title":"NEJM Evid"},{"key":"2026011203074142600_bib53","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa2310063","article-title":"Chronic lymphocytic leukemia therapy guided by measurable residual disease","volume":"390","author":"Munir","year":"2024","journal-title":"N Engl J Med"},{"key":"2026011203074142600_bib54","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1200\/JCO-25-00758","article-title":"Zanubrutinib and venetoclax for patients with treatment-na\u00efve chronic lymphocytic leukemia\/small lymphocytic lymphoma with and without del(17p)\/TP53 mutation: SEQUOIA arm D results","volume":"43","author":"Shadman","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026011203074142600_bib55","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1200\/JCO-24-02503","article-title":"Phase II study of acalabrutinib, venetoclax, and obinutuzumab in a treatment-na\u00efve chronic lymphocytic leukemia population enriched for high-risk disease","volume":"43","author":"Davids","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026011203074142600_bib56","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ccr.2007.07.001","article-title":"BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents","volume":"12","author":"Deng","year":"2007","journal-title":"Cancer Cell"},{"key":"2026011203074142600_bib57","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/416865a","article-title":"Increased proliferation of B cells and auto-immunity in mice lacking protein kinase Cdelta","volume":"416","author":"Miyamoto","year":"2002","journal-title":"Nature"},{"key":"2026011203074142600_bib58","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1182\/blood-2012-12-469544","article-title":"Loss-of-function of the protein kinase C \u03b4 (PKC\u03b4) causes a B-cell lymphoproliferative syndrome in humans","volume":"121","author":"Kuehn","year":"2013","journal-title":"Blood"},{"key":"2026011203074142600_bib59","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S1074-7613(00)00004-2","article-title":"Wnt signaling regulates B lymphocyte proliferation through a LEF-1 dependent mechanism","volume":"13","author":"Reya","year":"2000","journal-title":"Immunity"},{"key":"2026011203074142600_bib60","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1182\/blood-2008-06-163303","article-title":"Dysregulation of Frizzled 6 is a critical component of B-cell leukemogenesis in a mouse model of chronic lymphocytic leukemia","volume":"113","author":"Wu","year":"2009","journal-title":"Blood"},{"key":"2026011203074142600_bib61","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1038\/leu.2011.362","article-title":"Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells","volume":"26","author":"Daneshmanesh","year":"2012","journal-title":"Leukemia"},{"key":"2026011203074142600_bib62","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1182\/blood-2016-04-712562","article-title":"High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia","volume":"128","author":"Cui","year":"2016","journal-title":"Blood"},{"key":"2026011203074142600_bib63","doi-asserted-by":"crossref","first-page":"21631","DOI":"10.18632\/oncotarget.7795","article-title":"High LEF1 expression predicts adverse prognosis in chronic lymphocytic leukemia and may be targeted by ethacrynic acid","volume":"19","author":"Wu","year":"2016","journal-title":"Oncotarget"},{"key":"2026011203074142600_bib64","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1158\/0008-5472.CAN-12-1752","article-title":"The planar cell polarity pathway drives pathogenesis of chronic lymphocytic leukemia by the regulation of B-lymphocyte migration","volume":"73","author":"Kauck\u00e1","year":"2013","journal-title":"Cancer Res"},{"key":"2026011203074142600_bib65","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1182\/blood-2011-03-345165","article-title":"Differential niche and Wnt requirements during acute myeloid leukemia progression","volume":"118","author":"Lane","year":"2011","journal-title":"Blood"},{"key":"2026011203074142600_bib66","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s40164-024-00483-w","article-title":"The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt\/\u03b2-catenin signaling","volume":"13","author":"Marr","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"2026011203074142600_bib67","doi-asserted-by":"crossref","first-page":"e0125429","DOI":"10.1371\/journal.pone.0125429","article-title":"Characterization of LEF1 high expression and novel mutations in adult acute lymphoblastic leukemia","volume":"10","author":"Guo","year":"2015","journal-title":"PLoS One"},{"key":"2026011203074142600_bib68","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1365-2141.2007.06667.x","article-title":"Activation of Wnt\/beta-catenin pathway mediates growth and survival in B-cell progenitor acute lymphoblastic leukaemia","volume":"138","author":"Khan","year":"2007","journal-title":"Br J Haematol"},{"key":"2026011203074142600_bib69","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ccr.2007.11.003","article-title":"Loss of \u03b2-catenin impairs the renewal of normal and CML stem cells in vivo","volume":"12","author":"Zhao","year":"2007","journal-title":"Cancer Cell"},{"key":"2026011203074142600_bib70","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/s41375-019-0404-1","article-title":"Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options","volume":"33","author":"van Andel","year":"2019","journal-title":"Leukemia"},{"key":"2026011203074142600_bib71","first-page":"1433","article-title":"High expression and nuclear localization of \u03b2-catenin in diffuse large B-cell lymphoma","volume":"5","author":"Ge","year":"2012","journal-title":"Mol Med Rep"},{"key":"2026011203074142600_bib72","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.stem.2012.02.017","article-title":"Genetic and pharmacologic inhibition of \u03b2-catenin targets imatinib-resistant leukemia stem cells in CML","volume":"10","author":"Heidel","year":"2012","journal-title":"Cell Stem Cell"},{"key":"2026011203074142600_bib73","doi-asserted-by":"crossref","first-page":"11009","DOI":"10.1074\/jbc.M110.180208","article-title":"Evidence of a role for activation of Wnt\/beta-catenin signaling in the resistance of plasma cells to lenalidomide","volume":"286","author":"Bjorklund","year":"2011","journal-title":"J Biol Chem"},{"key":"2026011203074142600_bib74","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1177\/1947601910362446","article-title":"Wnt\/\u03b2-catenin pathway modulates the sensitivity of the mutant FLT3 receptor kinase inhibitors in a GSK-3\u03b2 dependent manner","volume":"1","author":"Jiang","year":"2010","journal-title":"Genes Cancer"},{"key":"2026011203074142600_bib75","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"key":"2026011203074142600_bib76","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2022016040","article-title":"Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy","volume":"140","author":"Thijssen","year":"2022","journal-title":"Blood"},{"key":"2026011203074142600_bib77","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3324\/haematol.2023.284353","article-title":"LP-118 is a novel B-cell lymphoma 2\/extra-large inhibitor that demonstrates efficacy in models of venetoclax-resistant chronic lymphocytic leukemia","volume":"110","author":"Ravikrishnan","year":"2025","journal-title":"Haematologica"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-25-0114\/3668591\/bcd-25-0114.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-25-0114\/3715460\/bcd-25-0114.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/7\/1\/85\/3723385\/bcd-25-0114.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/7\/1\/85\/3723385\/bcd-25-0114.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T08:08:00Z","timestamp":1768205280000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/7\/1\/85\/771361\/PKC-Inhibitor-MS-553-Displays-Preclinical-Efficacy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,11,5]]},"published-print":{"date-parts":[[2026,1,12]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-25-0114","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2643-3230.31047018","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31047039","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31047006","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31047009","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31047036","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31047057","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31047024","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31047027","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31047015","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31047048","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31047054","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31047021","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31047012","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31047045","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31047033","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31047060","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31047063","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31047030","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.31047051","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2643-3230.c.8239509","asserted-by":"object"}]},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]}}}